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Protein kinases are one of the most successfully targeted protein families with over 30 different FDA-approved drugs on the market and many more undergoing testing in the clinic. Despite this success, there are many challenges to overcome to identify potent, selective inhibitors with good pharmacokinetics. An area that has not yet been exploited widely and that offers opportunities to overcome these challenges is the idea of targeting the kinases outside the ATP site.
Chronic myelogenous leukemia (CML) is characterized by a chromosomal translocation resulting in fusion of the BCR and ABL1 genes and constitutive activation of ABL1 kinase. This fatal disease has been transformed into a chronic condition for a majority of patients due to the discovery of tyrosine kinase inhibitors (TKI), targeting the ATP site of the kinase. However, there remains a subset of patients who develop resistance or who do not tolerate these drugs.
The molecular understanding of the regulation of ABL1 kinase enabled us to design biophysical and biochemical assays that could replicate the effects of blocking the kinase in a physiologically relevant inactive conformation. This resulted in the discovery of ABL001 which binds with single digit nM affinity to a pocket distant from the ATP site and is active against known clinically relevant mutations in CML. ABL001 is currently being evaluated in Phase 1 clinical trials.
This case study highlights an example of the synergy between biophysics and medicinal chemistry in delivering potentially better drugs, and also demonstrates how an improved molecular understanding of the target can lead to novel modes of targeting proteins. Crystal structure prediction is the task of deriving the observable three-dimensional crystal structures of organic molecules from their chemical structure alone. Prediction methods face the mathematical challenge of sampling a search space that grows exponentially with the number of degrees of freedom and the physical challenge of calculating lattice free energy differences with an accuracy that should be better than the order of magnitude of typical lattice energy differences between polymorphs.
The state-of-the-art was assessed by a series of blind tests in 1999, 2001, 2004, 2007, 2010 and 2015. In the last three blind tests, the highest success rate was scored with an approach implemented in the computer program GRACE. Dispersion-corrected density functional theory (DFT-D) calculations [1] are used to first generate reference data to which a tailor-made force field is fitted from scratch [2] for every chemical compound under consideration. The tailor-made force field is then used in conjunction with a Monte Carlo parallel tempering algorithm to generate crystal structures that are further optimized at DFT-D level. Statistical control mechanisms ensure that all crystal structures in a user-defined target energy window are found with a user-defined level of confidence.
The 2015 blind test [3] has demonstrated the ability of GRACE to perform crystal structure predictions using fully automated workflows, to handle two flexible molecules per asymmetric unit and to predict the crystal structure of the hydrate of a chloride salt.
Looking back on a dozen case studies published on drug-like molecules by various authors and an equal number of confidential studies with GRACE, a picture emerges how crystal structure prediction in an industrial working environment helps to rationalize crystallization behaviour, to understand solid-state forms, to solve crystal structures and to flag missing more stable forms. The emerging ability to find new crystal forms by rational crystallization experiment design based on the knowledge of the computed crystal energy landscape is illustrated by the example of Dalcetrapib [4] . 6, art7793 (2015) 
